extraskeletal Ewing sarcoma

Extraskeletal Ewing sarcoma is a rare malignant neoplasm primarily affecting soft tissues, often seen in children and young adults. It most commonly arises in the paravertebral region, chest wall, pelvis, and lower extremities. Treatment typically involves local excision, with consideration for postoperative chemotherapy and/or radiotherapy. Currently, no specific genes have been identified, and the inheritance pattern remains unclear. Prevalence data is not well characterized, which contributes to the challenges in understanding this condition.

The documentation for extraskeletal Ewing sarcoma is limited due to its rarity, affecting fewer than 5 people per million annually. The lack of systematic clinical studies and the absence of identified genetic factors have hindered comprehensive understanding and characterization of this condition. This makes it challenging for patients and families to find detailed information and support.

There are several orphan drugs in development for extraskeletal Ewing sarcoma, including (E)-N¿-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate and antinuclear antibody conjugated liposomal doxorubicin. Additionally, there is one active clinical trial for this condition. You can explore ongoing research and potential participation opportunities at ClinicalTrials.gov using this link: https://clinicaltrials.gov/search?cond=extraskeletal%20Ewing%20sarcoma.